Login to Your Account



Clinic Roundup


Monday, June 24, 2013
• Seattle Genetics Inc., of Bothell, Wash., reported data at the International Conference on Malignant Lymphoma in Lugano, Switzerland, including results from a Phase II trial testing PET-adapted sequential therapy with CD30-targeted antibody-drug conjugate Adcetris (brentuximab vedotin), augmented by the ICE chemo regimen (ifosfamide, carboplatin and etoposide), which showed that 79 percent of 33 evaluable patients obtained a complete remission, including 10 patients who achieved PET-normalization (PET-N) following treatment with Adcetris alone and 16 patients who achieved PET-N following the sequential treatment program.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription